Abstract
The identification of effective medications for the management of cocaine use disorders remains an unmet public health challenge. In view of the prominent role of dopaminergic mechanisms in cocaine’s abuse-related effects, research has focused on the development of subtype-selective dopamine D1-4 receptor antagonists. Here, we briefly recap the current status of this research effort, with a focus on several aspects of D4 research that may be pertinent to the consideration of D4 ligands in the development of candidate medications. Additionally, we present data from selfadministration studies in nonhuman primates showing that intravenous cocaine-maintained behavior is moderately, though non-significantly, decreased by doses of the D4-selective partial agonist Ro10-5824 and dramatically reduced by the D4- selective receptor antagonist NGD-94-1. The effects of these D4 ligands on cocaine self-administration were consistent among subjects and occurred in the absence of comparable effects on food-maintained responding. These data suggest that available D4 receptor antagonists should be investigated further as candidate medications for the management of cocaine use disorders.
Keywords: Cocaine use disorders, dopamine D4 receptor antagonists, L-745, 870 (3-([4-(4-chlorophenyl)piperazin-1-yl]methyl)-1Hpyrrolo[ 2, 3-b]pyridine, NGD-94-1 ( 2-[4-[(2-Phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]-pyrimidine), Nonhuman primates, Ro10-5824 (2-methyl-5-[(4-phenyl-3, 6-dihydro-2H-pyridin-1-yl)methyl]pyrimidin-4-amine), Self-administration.
CNS & Neurological Disorders - Drug Targets
Title:Dopamine D4 Receptor Antagonists for the Treatment of Cocaine Use Disorders
Volume: 14 Issue: 6
Author(s): Jack Bergman and Curtis G. Rheingold
Affiliation:
Keywords: Cocaine use disorders, dopamine D4 receptor antagonists, L-745, 870 (3-([4-(4-chlorophenyl)piperazin-1-yl]methyl)-1Hpyrrolo[ 2, 3-b]pyridine, NGD-94-1 ( 2-[4-[(2-Phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]-pyrimidine), Nonhuman primates, Ro10-5824 (2-methyl-5-[(4-phenyl-3, 6-dihydro-2H-pyridin-1-yl)methyl]pyrimidin-4-amine), Self-administration.
Abstract: The identification of effective medications for the management of cocaine use disorders remains an unmet public health challenge. In view of the prominent role of dopaminergic mechanisms in cocaine’s abuse-related effects, research has focused on the development of subtype-selective dopamine D1-4 receptor antagonists. Here, we briefly recap the current status of this research effort, with a focus on several aspects of D4 research that may be pertinent to the consideration of D4 ligands in the development of candidate medications. Additionally, we present data from selfadministration studies in nonhuman primates showing that intravenous cocaine-maintained behavior is moderately, though non-significantly, decreased by doses of the D4-selective partial agonist Ro10-5824 and dramatically reduced by the D4- selective receptor antagonist NGD-94-1. The effects of these D4 ligands on cocaine self-administration were consistent among subjects and occurred in the absence of comparable effects on food-maintained responding. These data suggest that available D4 receptor antagonists should be investigated further as candidate medications for the management of cocaine use disorders.
Export Options
About this article
Cite this article as:
Bergman Jack and Rheingold G. Curtis, Dopamine D4 Receptor Antagonists for the Treatment of Cocaine Use Disorders, CNS & Neurological Disorders - Drug Targets 2015; 14 (6) . https://dx.doi.org/10.2174/1871527314666150529132723
DOI https://dx.doi.org/10.2174/1871527314666150529132723 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microbial Biofilms: Impact on the Pathogenesis of Periodontitis, Cystic Fibrosis, Chronic Wounds and Medical Device-Related Infections
Current Topics in Medicinal Chemistry Inpatient Diabetes Management in Non-ICU Settings: Evidence and Strategies
Current Diabetes Reviews IL-27: Friend or Foe in the Autoimmune Diseases
Current Immunology Reviews (Discontinued) Conference Report: Nanotechnology Congress & Expo 2015, Frankfurt, Germany August 11-13, 2015
CNS & Neurological Disorders - Drug Targets A Sweeping Role for MicroRNAs in Neuronal Disease, Vascular Disorders, and as Prognostic Indicators
Current Neurovascular Research Epigenetic Mechanisms Underlying Diet-Sourced Compounds in the Prevention and Treatment of Gastrointestinal Cancer
Anti-Cancer Agents in Medicinal Chemistry Meldrum's Acid in Organic Synthesis, an Outlook to Reaction Media
Current Organic Chemistry Antibody Gene Therapy: Getting Closer to Clinical Application?
Current Gene Therapy Curcumin Therapeutic Modulation of the Wnt Signaling Pathway
Current Pharmaceutical Biotechnology Intracellular Retention of Three Quinuclidine Derivatives in Caco-2 Permeation Experiments: Mechanisms and Impact on Estimating Permeability and Active Efflux Ratio
Drug Metabolism Letters Psychoeducation in Subjects at Elevated Risk for Psychosis - A Critical Review
Current Pharmaceutical Design Development of Molecular Probes for Imaging Sigma-2 Receptors in Vitro and in Vivo
Central Nervous System Agents in Medicinal Chemistry Pharmacogenomics and Sepsis-Induced Renal Failure: Effects of β 2-Adrenoceptor Function on the Course of Sepsis
Current Pharmacogenomics and Personalized Medicine Meet Our Editorial Board Member
Current Alzheimer Research Meet Our Co-Editor
Current Enzyme Inhibition Metabotropic Glutamate Receptor 7 (mGluR7) as a Target for the Treatment of Psychostimulant Dependence
CNS & Neurological Disorders - Drug Targets Kallikrein-Kinin System Mediated Inflammation in Alzheimers Disease In Vivo
Current Alzheimer Research SkQ-1 Regulates Xanthine Oxidase Activity in the Settings of Epilepsic Seizures in Rats
Neuroscience and Biomedical Engineering (Discontinued) Ameliorative Effect of Phosphodiesterase-5 Inhibitor in Rat Model of Vascular Dementia
Current Neurovascular Research Cerebral Acetylcholinesterase Imaging: Development of the Radioprobes
Current Topics in Medicinal Chemistry